Search

Displaying results 3501 - 3510 of 8575 in total
  1. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.

  2. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

    Products: Amicar Tab 500mg, Amicar - Tab, 500mg
  3. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are...

  4. Drug

    Flurpiridaz F-18

    go.drugbank.com/drugs/DB18773
    Approved

    Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected coronary artery disease (CAD). Fl...

  5. Drug

    Danoprevir

    go.drugbank.com/drugs/DB11779
    Investigational

    Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.

  6. Drug

    WIN 55212-2

    go.drugbank.com/drugs/DB13950
    Experimental

    WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical … It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling.

  7. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  8. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2...

  9. Drug

    Iobitridol

    go.drugbank.com/drugs/DB12407
    ApprovedWithdrawn

    Iobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.

  10. Drug

    Tilarginine

    go.drugbank.com/drugs/DB11815
    ApprovedInvestigationalWithdrawn

    Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.